EP0870768B1 — Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
Assigned to Pfizer Inc · Expires 2002-05-15 · 24y expired
What this patent protects
Compounds of formula I are useful in treatment of conditions associated with depletion of nicotine receptors in mammals. <CHEM> wherein X is: a) -CH2NR<1>R<2>, b) <CHEM> or; c) <CHEM> and R,R<1> and R<2> are independently selec…
USPTO Abstract
Compounds of formula I are useful in treatment of conditions associated with depletion of nicotine receptors in mammals. <CHEM> wherein X is: a) -CH2NR<1>R<2>, b) <CHEM> or; c) <CHEM> and R,R<1> and R<2> are independently selected from hydrogen and C1-C6 alkyl; R<3> is selected from hydrogen, halogen and C1-C6 alkyl; l is an integer from 0-4;m is an integer from 0-4; and n is an integer from 0-2; or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.